Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

ClinicalTrials.gov ID: NCT01186744

Public ClinicalTrials.gov record NCT01186744. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multi-Site, Randomized, Mixed-Blind, Parallel-Group Treatment Withdrawal And Re-Treatment Study Of The Efficacy And Safety Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objectives of the study are to 1) compare the efficacy responses of CP 690,550 (5 mg BID and 10 mg BID) versus placebo following 24 weeks of CP 690,550 treatment and subsequent withdrawal of active treatment at various timepoints during the 16 week double blind active or placebo treatment period; 2) evaluate the regain of efficacy responses of CP 690,550 (5 mg BID and 10 mg BID) following 4 -16 weeks of CP 690,550 treatment withdrawal and subsequent re treatment; and 3) evaluate the safety and tolerability of CP 690,550 (5 mg BID and 10 mg BID) in subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.

Study identification

NCT ID
NCT01186744
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
666 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 2010 (Type not available)
Primary completion
Jan 2013 (Actual)
Completion
Jan 2013 (Actual)
Last update posted
Dec 26, 2018

2010 – 2013

United States locations

U.S. sites
50
U.S. states
21
U.S. cities
36
Facility City State ZIP Site status
Horizon Research Group, Inc. Mobile Alabama 36608 —
Radiant Research, Inc. Tucson Arizona 85710 —
Center for Dermatology Clinical Research, Inc. Fremont California 94538 —
Associates In Research, Inc. Fresno California 93720 —
Dermatology Research Associates Los Angeles California 90045 —
Expresscare Medical Los Angeles California 90045 —
Dermatology Specialists, Inc. Oceanside California 92056 —
University of California San Francisco San Francisco California 94118 —
Longmont Clinic, PC Longmont Colorado 80501 —
New England Research Associates, LLC Trumbull Connecticut 06611 —
Florida Academic Dermatology Center Miami Florida 33136 —
International Dermatology Research, Inc. Miami Florida 33144 —
Park Avenue Dermatology, PA Orange Park Florida 32073 —
Ameriderm Research Ormond Beach Florida 32174 —
Miami Research Associates South Miami Florida 33143 —
Altman Dermatology Associates Arlington Heights Illinois 60005 —
Springfield Clinic, LLP Springfield Illinois 62703 —
Springfield Clinic Springfield Illinois 62703 —
Deaconess Clinic Downtown Evansville Indiana 47713 —
DMIA Louisville Kentucky 40207 —
DermResearch, PLLC Louisville Kentucky 40217 —
Quest Diagnostics Louisville Kentucky 40217 —
Northeast Dermatology Associates Beverly Massachusetts 01915 —
ActivMed Practices and Research, Inc. Haverhill Massachusetts 01830 —
Michigan Center for Research Corporation dba Michigan Center for Skin Care Research Clinton Township Michigan 48038 —
Minnesota Clinical Study Center Fridley Minnesota 55432 —
Comprehensive Clinical Research Berlin New Jersey 08009 —
Duke University Medical Center Durham North Carolina 27710 —
Dermatology Consulting Services High Point North Carolina 27262 —
Dermatology Associates Wilmington North Carolina 28401 —
New Hanover Medical Group, PA Wilmington North Carolina 28401 —
New Hanover Medical Research Wilmington North Carolina 28401 —
PMG Research of Wilmington LLC Wilmington North Carolina 28401 —
Piedmont Imaging Winston-Salem North Carolina 27103 —
Piedmont Medical Research Winston-Salem North Carolina 27103 —
Triad Dermatology, PA Winston-Salem North Carolina 27103 —
Jewish Hospital Cincinnati Ohio 45236 —
Radiant Research, Inc. Cincinnati Ohio 45249 —
University Hospitals Case Medical Center Cleveland Ohio 44106 —
Oregon Medical Research Center, PC Portland Oregon 97223 —
Rhode Island Hospital Providence Rhode Island 02903 —
Medical Research South, LLC Charleston South Carolina 29407 —
Office of Marta T. Hampton, MD Charleston South Carolina 29407 —
Dermatology & Laser Center of Charleston Charleston South Carolina 29414 —
Office of John Michael Humeniuk, MD Greer South Carolina 29650 —
Radiant Research, Inc. Greer South Carolina 29651 —
Dermatology Research Associates Nashville Tennessee 37203 —
Office of Stephen Miller, MD, PA San Antonio Texas 78229 —
Center for Clinical Studies Webster Texas 77598 —
Mountain State Clinical Research Clarksburg West Virginia 26301 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01186744, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 26, 2018 · Synced Oct 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01186744 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →